Premium
Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
Author(s) -
Jiménez Pilar,
Cantón Julia,
Collado Antonia,
Cabrera Teresa,
Serrano Alfonso,
Real Luis Miguel,
García Angel,
RuizCabello Francisco,
Garrido Federico
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990924)83:1<91::aid-ijc17>3.0.co;2-4
Subject(s) - loss of heterozygosity , biology , locus (genetics) , microsatellite , human leukocyte antigen , genetics , cancer research , chromosome , haplotype , population , allele , antigen , gene , medicine , environmental health
Loss of heterozygosity (LOH) in the short arm of chromosome 6 (6p) was detected in samples obtained from colon (13.8%), larynx (17.6%) and melanoma (15.3%) tumors. The parallel study of HLA‐antigen expression in tumor tissues using locus‐ and polymorphic‐specific antibodies in combination with LOH microsatellite analysis on 6p allowed us to establish that LOH in chromosome 6 is a representative phenomenon in most tumor cells present in a given tumor tissue. In most cases, specific HLA alleles had been lost in a predominant population of tumor cells, indicating that LOH is a non‐irrelevant mutation that probably confers a selective advantage for survival of the mutant cell. We also demonstrate that LOH frequently occurred through chromosome loss rather than somatic recombination. LOH at all loci studied on the p and q arms of chromosome 6 was observed in at least 56.2% (9/17) cases. This HLA‐associated microsatellite analysis was a useful tool for classifying tumors as LOH‐positive or ‐negative, and therefore to consider a patient as a potential non‐responder or responder in a vaccination trial. Int. J. Cancer 83:91–97, 1999. © 1999 Wiley‐Liss, Inc.